Carbocisteine
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Carbocisteine: From Mucolytic Use (Original Indication Not Recorded) to Gout
One-Sentence Summary
Carbocisteine is a mucoregulatory drug, and its original indication is not recorded in the source data. The TxGNN model predicts it may be effective for Gout with a very high score (99.67%), but 0 clinical trials and 0 publications support this direction, so it is a model prediction only.
Quick Overview
| Item | Content |
|---|---|
| Predicted New Indication | Gout |
| TxGNN Prediction Score | 99.67% |
| Evidence Level | L5 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Carbocisteine is a mucoregulator, and the literature describes improved mucociliary transport, reduced mucin (MUC5AC) expression and reactive oxygen species scavenging. These effects relate to airway disease.
No mechanistic link to urate metabolism or gouty inflammation has been established for carbocisteine. The high score is a knowledge-graph output only, and no study supports it. It should not be read as pharmacological plausibility. A similarly high score for Lesch-Nyhan syndrome (a purine-metabolism disorder) suggests the two predictions may share the same graph artefact.
Note on the other predictions: The only prediction with substantial evidence is bronchitis (rank 2, score 98.77%, Evidence Level L1). It rests on a 2019 Cochrane review of mucolytics versus placebo, a 2024 systematic review and meta-analysis in stable COPD, and a 1985 double-blind long-term trial. This is likely an established, on-label use rather than true repurposing. Only titles and abstracts were available, so effect size and risk of bias have not been assessed. Laryngitis (rank 8) has indirect upper-airway evidence only and is a research question at most.
Clinical Trial Evidence
Currently no related clinical trials registered for gout.
Literature Evidence
Currently no related literature available for gout.
South Africa Market Information
| Registration Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| M/10.1/248 | Flemex | Syrup | Not stated in the register extract |
Essential Medicines List (EML) status could not be determined from the available data.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
No drug-interaction records were found in the queried source.
Conclusion and Next Steps
Decision: Hold
Rationale: The gout prediction rests only on a knowledge-graph score. It has no trials, no literature and no plausible mechanistic link to urate metabolism, so it does not justify further investment now.
To proceed, the following is needed:
- A mechanistic rationale linking carbocisteine to urate handling or gouty inflammation, and any preclinical data
- SAHPRA package insert warnings and contraindications (currently a blocking gap for safety screening)
- Mechanism of action data from DrugBank
- The original approved indication, as the register entry has no indication text
- If the bronchitis or COPD use is of interest, a separate evaluation with reviewer confirmation of the systematic review evidence
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.